#London #United Kingdom #Brenig Therapeutics #AI Drug Discovery #Keystone Symposia

Brenig Therapeutics to Present Hybrid AI Drug Discovery Platform

Brenig Therapeutics Inc., a forward-thinking clinical-stage biotechnology firm, is ready to present its cutting-edge hybrid AI drug discovery platform at the prestigious Keystone Symposia titled "Computational Advances in Drug Discovery." The event, set for May 8, 2026, in London, showcases the company's innovative approach to developing treatments for a range of neurodegenerative, neuroinflammatory, and cardiometabolic disorders.

Dr. Alexei Pushechnikov, a key figure at Brenig, will lead a presentation titled "The Convergence of Structural Biology and Non-Human Intelligence in Brenig Therapeutics' Early Discovery." This presentation aims to illustrate how Brenig combines traditional structural biology with modern artificial intelligence to solve persistent challenges in drug discovery.

The hybrid AI platform is a product of collaboration with Expert Systems, Inc., and focuses on integrating physics-based structural insights with advanced machine learning techniques. This synergy is designed to streamline drug design processes, allowing for the effective creation of small molecules that exhibit high selectivity and brain penetration—an area that has historically represented a significant challenge in developing medications for central nervous system (CNS) diseases.

In particular, the platform emphasizes the ability to balance several crucial factors in drug development: potency, selectivity, and CNS exposure. By leveraging molecular dynamics combined with large-scale AI-driven property optimization, Brenig simplifies the design-make-test cycle, enhancing the efficiency of drug creation. This concurrent co-optimization approach empowers researchers to refine multiple parameters—ranging from potency, selectivity, safety, to CNS exposure—simultaneously.

Dr. Pushechnikov elaborates, "Brenig was founded on the premise that integrating rigorous physics with cutting-edge AI can transform drug discovery. Our partnership with Expert Systems allows us to harness an extraordinary discovery engine that navigates chemical landscapes with unparalleled precision and efficiency."

The pioneering platform has already propelled several developmental programs into clinical stages within a mere three years. Among these, the standout programs include:

1. BT-267: A potent LRRK2 inhibitor tailored specifically for Parkinson's disease.
2. BT-409: A NLRP3 inhibitor targeting both neuroinflammatory and cardiometabolic conditions, which was initially discovered by Mwyngil Therapeutics and further advanced by Brenig into clinical trials.

These developments underscore Brenig's commitment to refining compounds that exhibit optimized pharmacological characteristics while pursuing the goal of delivering best-in-class therapies. Additionally, the company plans to share insights demonstrating how this hybrid approach helps tackle historically daunting challenges in developing CNS drugs, such as achieving high selectivity across the kinome coupled with robust brain exposure.

Dr. Megan McGill, the CEO of Brenig Therapeutics, affirms the robustness of their discovery engine, stating, "This isn't just a theoretical framework—it has already yielded clinical assets with distinct profiles. Our partnership with Expert Systems has allowed us to create an optimized drug discovery approach that consistently delivers top-tier medicines."

As Brenig Therapeutics prepares for its presentation at the Keystone Symposia, the anticipation builds around the potential contributions of their hybrid AI platform to the broader landscape of drug discovery and development. With its innovative strategies and dedication to improving healthcare outcomes for patients with neurological diseases, Brenig is poised to make significant impacts in the biotechnology sector.

Conclusion

With the commencement of new programs and ongoing clinical trials, Brenig Therapeutics stands at the forefront of the next generation of drug discovery, showcasing how the integration of artificial intelligence with robust scientific principles can lead to revolutionary advancements in treating debilitating diseases. The company is not only changing how we think about drug discovery but also paving new paths toward potentially life-changing therapies for millions around the globe.